June 2021
Volume 62, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2021
Safety of multiple intravitreal injections of ocriplasmin in subjects with non–proliferative diabetic retinopathy (NPDR): Results of the CIRCLE study.
Author Affiliations & Notes
  • Mahi Muqit
    NIHR Moorfields Biomedical Research Centre, London, Greater London, United Kingdom
  • Ramin Tadayoni
    Hopital Lariboisiere, Paris, Île-de-France, France
  • J Hamouz
    Fakultni nemocnice Kralovske Vinohrady, Praha, Praha, Czechia
  • Victor H Gonzalez
    Valley Retina Institute, McAllen, Texas, United States
  • Javier Montero
    Hospital Universitario Rio Hortega, Valladolid, Castilla y León, Spain
  • David Scales
    Foresight Studies, LLC, San Antonio, Texas, United States
  • Geeta V Menon
    Frimley Health NHS Foundation Trust, Frimley, Surrey, United Kingdom
  • Prema Abraham
    Black Hills Regional Eye Institute, Rapid City, South Dakota, United States
  • Timothy L Jackson
    King's College Hospital, London, London, United Kingdom
  • Ivan Fiser
    Evropska ocni klinika Lexum, Czechia
  • Petra Kozma-Wiebe
    Oxurion NV, Leuven, Belgium
  • Footnotes
    Commercial Relationships   Mahi Muqit, Thrombogenics (F); Ramin Tadayoni, Thrombogenics (F); J Hamouz, Thrombogenics (F); Victor Gonzalez, Thrombogenics (F); Javier Montero, Thrombogenics (F); David Scales, Thrombogenics (F); Geeta Menon, Thrombogenics (F); Prema Abraham, Thrombogenics (F); Timothy Jackson, Thrombogenics (F); Ivan Fiser, Thrombogenics (F); Petra Kozma-Wiebe, Oxurion (E)
  • Footnotes
    Support  Principle Investigator in the clinical study
Investigative Ophthalmology & Visual Science June 2021, Vol.62, 1083. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Mahi Muqit, Ramin Tadayoni, J Hamouz, Victor H Gonzalez, Javier Montero, David Scales, Geeta V Menon, Prema Abraham, Timothy L Jackson, Ivan Fiser, Petra Kozma-Wiebe; Safety of multiple intravitreal injections of ocriplasmin in subjects with non–proliferative diabetic retinopathy (NPDR): Results of the CIRCLE study.. Invest. Ophthalmol. Vis. Sci. 2021;62(8):1083.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : The CIRCLE study was conducted to assess the efficacy and the safety of up to 3 intravitreal (IVT) injections of ocriplasmin to induce total posterior vitreous detachment (PVD), in order to reduce the risk of disease progression to proliferative diabetic retinopathy (PDR). A single intravitreal injection of ocriplasmin 0.125mg is approved for the treatment of symptomatic vitreomacular adhesion (VMA)/vitreomacular traction (VMT).

Methods : The CIRCLE study was a multicenter, sham-controlled, double-masked study. Subjects were randomized 2:2:1 to receive up to 3 IVT injections of ocriplasmin 0.0625mg, ocriplasmin 0.125mg, or a sham procedure, 1 month apart. They were followed for 24 months.

Results : Recruitment in the study was stopped early due to a slow recruitment rate. As a result, the study was not powered for its primary endpoint (total PVD by Month 3) and the main goal became the assessment of the safety of up to 3 IVT injections of ocriplasmin. Forty-eight (48) subjects were randomized: 20 to ocriplasmin 0.0625mg, 19 to ocriplasmin 0.125mg and 9 to sham. The subjects were mostly white and male. The mean age at Baseline was 56.2 years. The mean time since the diagnosis of diabetes was 16.9 years. There were no relevant imbalances between treatment arms. The most frequently reported treatment–related adverse events (AEs) in the study eye were Conjunctival Haemorrhage in the ocriplasmin 0.0625mg arm (3 events in 3/20 [15.0%] subjects) and Vitreous Floaters in the ocriplasmin 0.125mg arm (5 events in 3/19 [15.8%] subjects). This is similar to the most frequently observed treatment–related AEs following a single injection of ocriplasmin 0.125mg in patients with symptomatic VMA/VMT. No new type of AE was identified. The majority of AEs were mild or moderate in intensity, started within the first week after injection and resolved within a few days. The frequency or intensity of AEs did not increase following the second or third injection with ocriplasmin.

Conclusions : Up to three (3) IVT injections with ocriplasmin were considered safe, given that no new type of AE unknown to ocriplasmin was identified, as compared to a single injection of ocriplasmin 0.125mg in patients with symptomatic VMA/VMT. Neither the frequency nor the intensity of the AEs increased following the second or third injection with ocriplasmin.

This is a 2021 ARVO Annual Meeting abstract.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×